NCT04521179View on ClinicalTrials.gov

Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

January 12, 2022

Study Completion Date

May 22, 2023

Conditions
HER2-positive Solid Tumors
Interventions
DRUG

KN026 combination

30 mg/kg Q3W KN026+ 5 mg/kg Q3W KN046

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Peking University

OTHER

lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY

NCT04521179 - Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors | Biotech Hunter | Biotech Hunter